Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Citadel Securities’ Fed Rate Hike Call Adds to Market Angst

View original at finance.yahoo.com
Citadel Securities’ Fed Rate Hike Call Adds to Market Angst (Bloomberg) -- On the eve of the Federal Reserve's policy decision, bond traders are on edge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is no good reason for the Fed not to raise interest rates.

    60% confidence
  • The market is probably underestimating the probability of a Fed move on Wednesday.

    60% confidence
  • Warsh is still kind of a wildcard, adamant about not wanting to provide forward guidance, but might inadvertently signal something.

    60% confidence
  • The Fed should rip off the band aid and raise rates by half a point, gaining inflation-fighting credibility while fending off pressure from President Trump to lower borrowing costs.

    60% confidence
  • Warsh has set the stage for a hike; putting off the decision now would raise the probability of a 50 basis point move in September.

    60% confidence
  • A rate hike would emphatically end the forward guidance era while underscoring the Fed's independence.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Citadel Securities’ Fed Rate Hike Call Adds to Market Angst — Source | Via News | ViaNews Market